

## GlobelImmune (GBIM : US\$3.65)

### GlobelImmune continues downtrend, plummets 52% in 2015

GlobelImmune Inc., NASDAQ's 56th largest Healthcare-Products company by market cap, plummeted US\$3.99 (or 52.2%) year to date in 2015 to close at US\$3.65. This means the stock is amongst the bottom 2% of NASDAQ-listed stocks in 2015.

Compared with the NASDAQ-100 Index which has risen 4.8% YTD, this is a relative price change of -57%. The volume YTD has been 1.1 times the average trading of 33,107 shares. In 2015 the market cap has declined US\$22.9 million.

### Introduction with Trends

**We are currently bearish on this stock, both in the short-term based on technical indicators, as well as in the long-term based on fundamental metrics**

**What makes us most bearish on the stock is the following:**

- Its Moving Average Convergence Divergence indicators are falling, with its 12-day EMA lower than its 26-day EMA.
- The price to 200-day MAP ratio is 0.29, a bearish indicator.
- In the last three months the number of falls outnumbered rises 32:30 or 1.07:1.

**However, there are some reasons why some in the market are more bullish on the stock:**

- Amongst stocks that are shorted, it was in the bottom quartile as a percentage of stock shorted, suggesting that there are fewer confident bears of the stock.
- "Current ratio of two or more"; current assets are 3.4 times current liabilities.

### stock Summary

<b>Sector</b>	Healthcare-Products
<b>Market Cap</b>	US\$21 million
<b>Shares Outstanding</b>	5,748,979
<b>Relative Strength (3 mo)</b>	1

### Financial Summary

Year ended	Dec 2014	Dec 2013	Dec 2012
Sales (USD M)	6	22.5	14.6
Pretax (USD M)	(16.3)	9.6	(2)
Net (USD M)	(23.4)	(3.4)	(14.1)
EPS (USD)	(8.0402)	(1.1955)	(157.9712)

### MCap: A Historical Perspective

	Share Price (USD)	Market Cap (US\$)
Last	3.6	21 million

## Analysis

### Bearish Signals

- Falls to Rises: In the last three months the number of falls outnumbered rises 32:30 or 1.07:1.
- In the last 10 trading sessions there has been a net decline of 50%; the stock has retreated nine times and the biggest one day decline was 49.7% on May 27.
- In the NASDAQ market of 2,382 stocks and 3 units traded today, the stock has a 6-month relative strength of 3 indicating it is trailing 97.0% of the market.
- The Moving Average Convergence Divergence (MACD) indicator of 12-day Exponential Moving Average (EMA) of 4.58 minus the 26-day EMA of 5.73 is negative suggesting a bearish signal. Both the 12-day EMA as well as the 26-day EMA are falling, another bearish signal.
- The Price/MAP of 0.29 for GBIM is lower than the Price/MAP for the NASDAQ-100 Index of 1.0.
- The price to 200-day MAP ratio is 0.29, a bearish indicator. In the past 200 days this ratio has been under 0.29 just once suggesting a support level. The 200-day MAP has decreased to US\$12.46. A decrease is another bearish indicator.

### Overvaluation:

- Price/Sales of 3.5 versus sector average of 1.4 and market average of 2.4. We estimate the shares are trading at a current year Price/Sales of 3.7 and a forward year Price/Sales of 3.9.

### Other Bearish Signals:

The stock has a score of merely 1 out of 9 set by Joseph Piotroski [pass mark  $\geq 5$ ]:

Improvement in current ratio from 1.1 to 3.4.

### Bearish Indicators and Rank in Market:

Description	Value	Rank In Market
Turnover in Quarter	US\$20.4 million	In Bottom Quartile
Volatility %	6.0	In Bottom Quartile
MCap	US\$21 million	In Bottom 4%
Annual Revenue	US\$6 million	In Bottom 4%
Relative Strength (6M)	3	In Bottom 2%
Price/MAP200	0.29	In Bottom 1%
Price/MAP50	0.25	In Bottom 1%

### Note

#### Bullish Signals:


- The price is at a discount of 17.4% to the 1-month volume weighted average price of US\$4.42, which may appeal as a value proposition.
- The stock is oversold according to the Williams % R indicator of -94.7.
- In the NASDAQ Short Selling market of 2394 stocks, short selling as a % of issued shares ranked 1947th and within the bottom quartile of stocks. This means it was lower than market average of 0.51%, a bullish indicator.
- The current short volume is 0.3 times its own historical average of 0.05%. It plummeted 96.8% from the previous day, plummeted 97.6% from a week ago, a bullish indicator.

#### Undervaluation:

- The Q Ratio, defined by James Tobin as MCap divided by Total Assets, is 1.1. Compared with the rest of the market the stock is undervalued.

### Other Bullish Signals:

#### % Growth Y.O.Y, Revenue & Net Profit



Also, the following criteria set by Benjamin Graham:


- "Current ratio of two or more"; current assets are 3.4 times current liabilities.

### Bullish Indicators and Rank in Market:

Description	Value	Rank In Market
Price Change %	2.5	In Top 9%

## Analysis (continued)


### Turnover Rate & Turnover Period



### Trailing 3 months

Turnover	US\$20.4 million
Volume	3,418,918
Volume Index (1 is avg)	1.6


### Weekly Price Volume Dynamics (Last 12 Weeks)




### Price/Moving Avg Price [P/MAP200]



### stock v Index (Trailing Year)



### YTD Comparison Stock Sector Index



## Peer Group Analysis

Name	Last Price	Relative Str. (6-months)	MCap (USD)	PV \$1000 (1 yr)	Revenue (USD)	Net Profit (USD)	Total Assets (USD)
Parnell Pharmaceuticals Holdings	US\$4.34	74	57.7M		7.5M	(13.3M)	36.7M
Aldeyra Therapeutics	US\$7.86	55	54.2M	1,291		(9.6M)	8.8M
Roka Bioscience	US\$2.44	5	44M		25,000	(29.6M)	59.1M
GlobelImmune	US\$3.65	3	21M		6M	(23.4M)	18.4M
Ruthigen	US\$4.34	58	20.9M	692		(3.1M)	15.6M
Reliv International	US\$1.16	39	14.9M	663	57.3M	724,569	26.8M
Signal Genetics	US\$1.57	3	12.2M		4.3M	(7.9M)	8.1M

## Company Overview

### Activities

Globelimmune Inc. operates as a biopharmaceutical company. The Company developing therapeutic products for cancer and infectious diseases, such as resected pancreas, non-small cell lung, colorectal, and medullary thyroid cancer, as well as multiple solid tumors.

Further details can be found at  
<http://www.globeimmune.com>.

Business Sector	Healthcare Services
Industry Group	Healthcare Equipment & Supplies
Economic Sector	Healthcare

### Regulatory Announcements

#### May 27: Globeimmune Announces Top Line Results From Gs-4774 Phase 2 Trial In Virally-suppressed Chronic Hbv Patients

[News Story] LOUISVILLE, CO -- (Marketwired) -- 05/27/15 -- Globelimmune, Inc.(NASDAQ:GBIM) today announced top line results from the GS-4774 Phase 2 study in patients with chronic hepatitis B on long term viral suppression with an oral antiviral treatment. In this study, patients treated with the highest dose of GS-4774 plus ongoing oral antiviral therapy (OAV) did not show a reduction in hepatitis B surface antigen (HBsAg) at week 24, the primary endpoint of the study, but at 48 weeks had a mean -0.17 log10 reduction of HBsAg compared with a -0.04 log10 reduction in the OAV alone group (p=not significant).

[For more details click here.](#)

#### May 14: Globelimmune: Globelimmune Announces First Quarter 2015 Results and Corporate Highlights

[News Story] LOUISVILLE, CO -- (Marketwired) -- 05/14/15 -- Globelimmune, Inc.(NASDAQ:GBIM) today announced its first quarter 2015 financial results and corporate highlights.

"We are pleased with the progress made across all of our programs," said Timothy C. Rodell, M.D., FCCP, President and CEO of Globelimmune, Inc.

[For more details click here.](#)

#### March 17: Globelimmune Announces Program Updates and Financial Results for Full Year 2014

[News Story] Globelimmune, Inc. (NASDAQ:GBIM) today provided an update on the Company's business and clinical programs, and announced financial results for the full year ended December 31, 2014.

"We are pleased with the progress made across all of our programs in 2014. Results reported from our Phase 1 trial of GI-6301 in metastatic cancers and chordoma were encouraging and we look forward to the initiation of the Phase 2 chordoma trial, as well as data from the GS-US-330-0101 HBV Phase 2 trial," said Timothy C.

[For more details click here.](#)

www.BuySellSignals.com

### Conferences/Exhibitions

#### March 02: Events Calendar: Globelimmune to Present at the 27th Annual ROTH Conference

[News Story] LOUISVILLE, CO 03/02/15 --

Globelimmune, Inc., (NASDAQ:GBIM) today announced that Timothy C. Rodell, M.D., Chief Executive Officer, will present at the 27th Annual ROTH Conference. Dr. Rodell will present at 12:30 p.m. PT on Monday, Mar. 9, 2015, at the Ritz Carlton Hotel in Laguna Niguel, Dana Point, CA.

A live audio webcast of the presentation will be available under the investor relations section of Globelimmune's website at <http://www.globeimmune.com/investors/events/>.  
[For more details click here.](#)

### Conferences/Exhibitions

#### February 03: Globelimmune to Present at the 17th Annual BIO CEO & Investor Conference

[News Story] LOUISVILLE, CO 02/03/15 -- Globelimmune, Inc., (NASDAQ:GBIM) today announced that Timothy C. Rodell, M.D., Chief Executive Officer, will present at the 17th Annual BIO CEO & Investor Conference. Dr. Rodell will present at 3 p.m. ET on Monday, Feb. 9, 2015, at the Waldorf Astoria Hotel in New York.

A live audio webcast of the presentation will be available under the investor relations section of Globelimmune's website at <http://www.globeimmune.com/investors/events/>.  
[For more details click here.](#)

### Financial Results

#### November 12 2014: Globelimmune Announces Third Quarter 2014 Financial Results

[News Story] LOUISVILLE, CO 11/12/14 -- Globelimmune, Inc.(NASDAQ:GBIM), today announced its third quarter 2014 financial results and corporate highlights.

<http://www.nasdaq.com/press-release/globeimmune-announces-third-quarter-2014-financial-results-20141112-00217>

Source: Nasdaq Stock Exchange

[For more details click here.](#)

#### September 30 2014: Globelimmune to Present at the 13th Annual BioInvestor Forum

[News Story] LOUISVILLE, CO 09/30/14 -- Globelimmune, Inc. (NASDAQ:GBIM) today announced that Timothy C. Rodell, M.D., Chief Executive Officer, will present at the 13th Annual BioInvestor Forum. Dr. Rodell will present at 9 a.m. PDT on Wednesday, Oct. 8, 2014, at the Palace Hotel in San Francisco, California.

A live audio webcast of the presentation will be available under the investor relations section of Globelimmune's website at <http://www.globeimmune.com/investors/events/>.



## Company Overview (continued)

### 8-K other news

#### May 27: Globelmmune: Other Events

[News Story]

[http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=\\_Archives\\_edgar\\_data\\_1245104\\_000119312515201136\\_0001193125-15-201136.txt](http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1245104_000119312515201136_0001193125-15-201136.txt)

Source: 8-K United States Securities and Exchange Commission

#### May 14: Globelmmune: Results of Operations and Financial Condition

[News Story]

[http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=\\_Archives\\_edgar\\_data\\_1245104\\_000119312515187031\\_0001193125-15-187031.txt](http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1245104_000119312515187031_0001193125-15-187031.txt)

Source: 8-K United States Securities and Exchange Commission

#### April 02: Globelmmune: Changes in Registrant's Certifying Accountant

[News Story]

[http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=\\_Archives\\_edgar\\_data\\_1245104\\_000119312515118044\\_0001193125-15-118044.txt](http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1245104_000119312515118044_0001193125-15-118044.txt)

Source: 8-K United States Securities and Exchange Commission

#### March 17: Globelmmune: Results of Operations and Financial Condition

[News Story]

[http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=\\_Archives\\_edgar\\_data\\_1245104\\_000119312515094793\\_0001193125-15-094793.txt](http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1245104_000119312515094793_0001193125-15-094793.txt)

Source: 8-K United States Securities and Exchange Commission

#### November 12: Globelmmune: Results of Operations and Financial Condition

[News Story]

[http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=\\_Archives\\_edgar\\_data\\_1245104\\_000119312514407977\\_0001193125-14-407977.txt](http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1245104_000119312514407977_0001193125-14-407977.txt)

Source: 8-K United States Securities and Exchange Commission

#### August 15: Globelmmune: Results of Operations and Financial Condition

[News Story]

[http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=\\_Archives\\_edgar\\_data\\_1245104\\_000119312514311820\\_0001193125-14-311820.txt](http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1245104_000119312514311820_0001193125-14-311820.txt)

Source: 8-K United States Securities and Exchange Commission

#### July 09: Globelmmune: Entry into a Material Definitive Agreement

[News Story]

[http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=\\_Archives\\_edgar\\_data\\_1245104\\_000119312514264225\\_0001193125-14-264225.txt](http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1245104_000119312514264225_0001193125-14-264225.txt)

Source: 8-K United States Securities and Exchange Commission

### Sector Sorting

For Company searches, or for sorting by stocks and variables, an interactive version of today's Table is available [here](#)

### Issued Capital


Based on 5,748,979 issued equity shares the market capitalisation is US\$21 million. It is NASDAQ's 47th largest Healthcare-Products company by assets. The top twenty one shareholders hold 9.4% of the issued capital leaving a float of 90.6%.

#### Top 10 Shareholders


Name of Shareholder	No. of Shares	% Held
Ghost Tree Capital Llc	68,973	1.2
Wasatch Advisors Inc	53,686	0.93
J. Goldman & Co Lp	42,850	0.75
Goldman Sachs Group Inc	17,607	0.31
Spark Investment Management Llc	14,400	0.25
Dafna Capital Management Llc	9,445	0.16
Blackrock Institutional Trust Company N.A.	2,934	0.05
Morgan Stanley	2,010	0.03
Tower Research Capital Llc (Trc)	1,301	0.02
Citigroup Inc	797	0.01
<b>Total</b>	<b>214,003</b>	<b>3.72</b>

## Company Overview (continued)

### Top 20 Institutional Holdings



## Board and Management



**Timothy C. Rodell**  
CEO & President & Director

Timothy C. Rodell, M.D. has been our Chief Executive Officer and a member of our Board of Directors since April 2003 and has been our President since June 2005. From March 2002 until April 2003, Dr. Rodell worked with SMG, Inc., a pharmaceutical consulting firm. From November 1999 until February 2002, Dr. Rodell was President and Chief Executive Officer of RxKinetix, Inc., a private drug delivery company. From March 1996 until October 2000, he held a number of positions at OXIS International, Inc., a publicly-traded developer of biotech and pharmaceutical technologies and products, including Chief Technology Officer and Chairman and President of OXIS International, SA, the company's French subsidiary. From 1985 until 1995, Dr. Rodell was at Cortech, Inc., a publicly-traded biopharmaceutical company, where he was most recently Executive Vice President of Operations and Product Development. He currently serves on the Board of Directors of the Biotechnology Industry Organization. Dr. Rodell earned his M.D. from the University of North Carolina School of Medicine and is board certified in internal medicine and pulmonary medicine. He also completed post-doctoral fellowships in molecular biology and cell biology at the Eleanor Roosevelt Cancer Institute and the Webb Waring Institute, respectively. The Nominating and Corporate Governance Committee believes that Dr. Rodell possesses specific attributes that qualify him to serve as a member of our board of directors, including his experience as a medical doctor, his operational and management expertise, and his years of leadership experience.

**Augustine J. Lawlor**  
Director

Augustine J. Lawlor has been a member of our Board of Directors since June 2003. Mr. Lawlor has been a managing director of HealthCare Ventures LLC since June 2000. Prior to joining HealthCare Ventures, Mr. Lawlor served as Chief Operating Officer of LeukoSite Inc., a biotechnology company, from June 1997 to June 2000. Before joining LeukoSite, Mr. Lawlor served as Chief Financial Officer and Vice President of Corporate Development of Alpha-Beta Technology, Inc., a biotechnology company. He was also previously Chief Financial Officer and Vice President, Business Development, of BioSurface Technologies Corporation, a biofilm company. Mr. Lawlor serves on the Board of Directors of Cardiovascular Systems, Inc., a publicly-traded biopharmaceutical company. From May 2004 to July 2011 Mr. Lawlor served on the Board of Directors of Human Genome Sciences, Inc., a publicly-traded biopharmaceutical company, and a number of private companies. He received a B.A. from the University of New Hampshire and a master's degree in management from Yale University. The Nominating and Corporate Governance Committee believes that Mr. Lawlor's business, financial and leadership expertise, including his experience in the venture capital industry and his years of business leadership, give him the qualifications and skills to serve as a director, and are particularly important as the Company continues its drug development efforts.

**S. Edward Torres**  
Director

S. Edward Torres has been a member of our Board of Directors since November 2010. Mr. Torres has been a Managing Director of Lilly Ventures Fund I, LLC, a venture capital fund since March 2009. From January 2006 until February 2009, he was a Managing Director of Lilly Ventures while Lilly Ventures was wholly-owned by Eli Lilly and Company. From December 2001 until December 2005, Mr. Torres was a Principal with Lilly Ventures. Prior to his various roles with Lilly Ventures, Mr. Torres held a range of positions with Eli Lilly and Company from 1989 through 2001, which included operational finance, planning, mergers and acquisitions, business development and global marketing roles. He currently serves on the Board of Directors of Receptos, Inc., a publicly traded biopharmaceutical company, where Mr. Torres serves as the chairman of the Audit Committee and as a member of Compensation Committee. Mr. Torres currently serves on the Board of Directors of several private companies. Mr. Torres received a B.A. from Creighton University and an M.B.A. from the University of Michigan Business School. The Nominating and Corporate Governance Committee believes that Mr. Torres's business, financial and leadership expertise, including his experience in the venture capital industry and his years of business leadership, give him the qualifications and skills to serve as a director, and are particularly important as the Company continues its drug development efforts.



## Board and Management (continued)

### Dan Mitchell Director

Dan J. Mitchell has been a member of our Board of Directors since June 2003. Mr. Mitchell founded and is a Manager of Sequel Venture Partners, L.L.C., a venture capital firm formed in January 1997. Prior to founding Sequel Venture Partners, Mr. Mitchell was a founder of Capital Health Venture Partners, a health care focused venture capital firm, in October 1986 where he was a General Partner until 2006. From 2002 to 2009, he served on the Board of Directors of Replidyne, Inc., a publicly-traded pharmaceutical company acquired by Cardiovascular Systems, Inc. In February 2014, Mr. Mitchell joined the Board of Directors of ARCA biopharma, Inc., a publicly-traded pharmaceutical company, where Mr. Mitchell serves as a member of the Board of Directors' Audit Committee and Nominating and Corporate Governance Committee. Mr. Mitchell currently serves on the Board of Directors of several private companies. Mr. Mitchell holds a B.S. from the University of Illinois and an M.B.A. from the University of California at Berkeley. The Nominating and Corporate Governance Committee believes that Mr. Mitchell's business, financial and leadership expertise, including his experience in the venture capital industry and his years of business leadership, give him the qualifications and skills to serve as a director, and are particularly important as the Company continues its drug development efforts.

### J. William Freytag Chairman & Director

J. William Freytag, Ph.D. has served as Chairman of our Board of Directors since January 2011 and has served as a member of our Board of Directors since March 2008. Dr. Freytag served as a member of the Board of Directors of ARCA biopharma, Inc., a publicly-traded biopharmaceutical company, from January 2009 to March 2011, serving as chair and a member of its compensation committee and its Lead Director from January 2009 to March 2011. Dr. Freytag served as a director of Immunicon Corp., a publicly-traded developer of diagnostic products, as well as a member of its compensation committee, from May 1998 until its merger with Veridex, LLC in June 2008. Dr. Freytag was Chairman and Chief Executive Officer of Aspreva Pharmaceuticals Corp., a publicly-traded pharmaceutical company, from July 2007 until its merger with Galenica AG in January 2008. Prior to Aspreva, Dr. Freytag was President, Chief Executive Officer and Chairman of the Board of Directors of Myogen, Inc., a publicly-traded pharmaceutical company, from July 1998 until Myogen was acquired by Gilead Sciences, Inc. in November 2006. From November 2006 through June 2007, Dr. Freytag served as Senior Advisor to Gilead. From October 1994 to May 1998, Dr. Freytag was a Senior Vice President at Somatogen, Inc., a publicly-traded biotechnology company. Prior to Somatogen, he was President of Research and Development at Boehringer Mannheim Corporation, an international healthcare company, from May 1990 to September 1994. Previously, Dr. Freytag spent ten years with DuPont in various research and business positions in the Medical Products Department. Dr. Freytag received a B.S. from Purdue University and a Ph.D. in biochemistry from the University of Kansas Medical Center. The Nominating and Corporate Governance Committee believes that Dr. Freytag's scientific and business expertise, including his diversified background as an executive officer and investor in public pharmaceutical companies, give him the qualifications and skills to serve as a director, and are particularly important as the Company continues its drug development efforts.

# Financial Results (Annual)

31 December, 2014

## Annual Report: Globelimmune (NASDAQ:GBIM)<p><B>Highlights</B></p>

- Total liabilities to Total assets of 0.7
- EBIT to total assets of -67.3%

### Major Common Size Ratios:

- Total current assets to Total Assets up from 92.0% to 97.0%
- Cash to Total Assets up from 79.9% to 91.5%
- Fixed Assets to Total Assets down from 6.6% to 2.5%

### Unfavourable Changes:

- Total revenue down 73.5% to \$US6.0m
- EBIT loss of \$US12.4m
- EBIT Margin of -207.3%
- Losses in all of the last 5 years
- Operating Cash Flow is negative
- Total revenue to total assets down 89.3% to 0.3

Annual

Company Name : Globelimmune Inc. (GBIM)

December 31 Description	2014 \$US ('000)	2013 \$US ('000)	Change (%)
Total Revenue	5,966.4	22,518.4	down 73.5
EBIT	(12,370.3)	na	na
Interest	3,890.7	na	na
Current Liabilities	5,172.5	6,414.5	down 19.4
Total Liabilities	12,764.6	19,057.4	down 33.0
Non Current Debt	na	198.0	na
Performance Ratios			
Return on Equity (%)	(418.2)	na	na
Total Liabilities/Total Assets	0.7	na	na
Interest Cover	(3.2)	na	na
Common Size Ratios by Assets			
Total current assets to Total Assets (%)	97.0	92.0	Up 5.4
Cash to Total Assets (%)	91.5	79.9	Up 14.6
Fixed Assets to Total Assets (%)	2.5	6.6	Down 62.4
Common Size Ratios by Revenues			
Interest expenses to Revenues (%)	65.2	na	na
EBITDA to Revenues (%)	(92.6)	37.6	Down 346.5
EBIT to Revenues (%)	(207.3)	na	na
Profit before tax to Revenues (%)	(272.5)	42.6	Down 739.7

# Financial Results (Annual) (continued)

31 December, 2014

Profit after tax to Revenues (%)	(392.8)	(15.1)	Down 2495.1
Per Share figures			
EBIT	(\$US4.2)	na	na
Total Liabilities	\$US4.4	\$US6.7	down 34.5
Non Current Debt	na	6.9 U.S. cents	na

## Glossary

**Return on Equity (Shareholders' Funds):**

Net Profit/Net Assets (%)

**Price Close/Moving Av Price:**

Latest Price/Moving Average Price

**Price/Sales PS:**

Share Price/Sales Per Share (times)

**Interest Cover:**

Earnings Before Interest and Tax/Interest (times)

**Moving Average Price (n periods):**

Sum of Prices for each Period/Number of Periods

**Current Ratio:**

Current Assets/Current Liabilities (times)

**EBIT Margin :**

Earnings Before Interest and Tax/Revenue (%)

**Total Liabilities/Total Assets:**

Total Liabilities/Total Assets

BuySellSignals Financial Research provides equity research on over 48,000 companies listed in more than 90 countries and 120 markets across the world. BuySellSignals believes that every stock has a story to tell and that this story changes every day. To capture this story, BuySellSignals offers the latest pertinent and comprehensive information so that investors can make well-informed investment decisions.

BuySellSignals publishes equity research reports on each stock, sector and index daily to capture the latest market movements and sentiments. BuySellSignals eschews “hot tip” or headline investing in favour of high-quality, ultra-current, targeted technical and fundamental information including specific bullish and bearish signals for each stock. Insights that will guide you to the investments that are hard to find in today's hyperactive mainstream markets.

For further details on definitions and quotations from investing legends, [Click here](#)

Disclaimer: While this document is based on information sources which are considered reliable, it has been prepared without consideration of your specific investment objectives, financial situation or needs, so you should carry out your own analysis or seek professional investment advice before an investment decision is made. The document contains unbiased, independent equities data from BuySellSignals (AFS Licence 222756) and News Bites Pty Ltd, who provide round the clock data on every Australian stock and sector. Neither BuySellSignals nor News Bites are brokers, and neither have an executing, corporate advisory or investment banking function. BuySellSignals and News Bites Pty Ltd, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. The data is sourced from annual reports and company releases and may not be fully up to date. It should be used as a guide only.